Granulocyte Research Laboratory, Rigshospitalet 9322, 20 Juliane Maries vej, Copenhagen, Denmark.
J Leukoc Biol. 2012 Mar;91(3):495-500. doi: 10.1189/jlb.0811417. Epub 2011 Dec 20.
OLFM4 was identified initially as a gene highly induced in myeloid stem cells by G-CSF treatment. A bioinformatics method using a global meta-analysis of microarray data predicted that OLFM4 would be associated with specific granules in human neutrophils. Subcellular fractionation of peripheral blood neutrophils demonstrated complete colocalization of OLFM4 with the specific granule protein NGAL, and stimulation of neutrophils with PMA resulted in corelease of NGAL and OLFM4, proving that OLFM4 is a genuine constituent of neutrophil-specific granules. In accordance with this, OLFM4 mRNA peaked at the MY/MM stage of maturation. OLFM4 was, however, present in only 20-25% of peripheral blood neutrophils, as determined by immunocytochemistry and flow cytometry, whereas mRNA for OLFM4 was present in all MY/MM, indicating post-transcriptional regulation as a basis for the heterogeneous expression of OLFM4 protein.
OLFM4 最初被确定为一种在粒细胞集落刺激因子(G-CSF)治疗下高度诱导的髓系干细胞基因。一种使用全基因组微阵列数据分析的生物信息学方法预测,OLFM4 将与人类中性粒细胞的特异性颗粒相关。外周血中性粒细胞的亚细胞分离显示,OLFM4 与特异性颗粒蛋白 NGAL 完全共定位,用 PMA 刺激中性粒细胞导致 NGAL 和 OLFM4 的核心释放,证明 OLFM4 是中性粒细胞特异性颗粒的真正组成部分。与此一致,OLFM4 mRNA 在成熟的 MY/MM 阶段达到峰值。然而,通过免疫细胞化学和流式细胞术测定,OLFM4 仅存在于 20-25%的外周血中性粒细胞中,而 OLFM4 的 mRNA 存在于所有 MY/MM 中,表明转录后调节是 OLFM4 蛋白异质性表达的基础。